This is from a company in Norway and is entering phase III trials with these results, it is not that large of a sampling group and will have to pass phase IV before it may make it to market. Men given this injection of radium-223 (a type of radiation injection-apparently) did pretty well with its useage, in PCa anything of results is considered worth looking at and comparing.
Article says men (treated) vs. placebo men had double the survival time, or course more studies and larger sampling is needed on this, along with any possible side effects or negatives to be noted.
This method is used on hrpca (refractive patients)-those who no longer respond to the normal LHRH and casodex types of drugs, but could have response to other drugs that do work against hrpca's just so the record is clear, this trial was on hrpca only. So if people were maybe taking this injection while not considered hrpca the results could even be better (logically thinking, but in PCa that usually does not hold alot of water, but might).
There are alot of trials out there, with trials phase 1 and 2 sometimes decent proprosed protocols sometimes get the axe, and perhaps without all the correct reasons, but that could be a whole discussion, thing. We look for good results from whatever trials are going on.
Post Edited (zufus) : 2/7/2009 5:36:41 AM (GMT-7)